STAFFORD, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Microvast Holdings, Inc. (NASDAQ: MVST), (“Microvast” or the “Company”), a global leader in advanced battery technologies, will issue a press release reporting its consolidated financial results for the third quarter of 2025 after market close on Monday, November 10, 2025. Following the earnings press release, Microvast management will host a webcast and earnings conference call at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss the business resu ...

Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide in Combin ...

Strong Revenues and Adjusted EBITDA growth in Experiential Services partially offsetting softness in Branded Services Generated $98 million in adjusted unlevered free cash flow and ended the quarter with strong cash position of $201 million Rapidly responded to robust demand in high-volume labor businesses generating strong incremental margin Reaffirm Revenue and modestly lower Adjusted EBITDA outlook due to impact of divestiture and macro environment ST. LOUIS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Advantage ...

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology compa ...

Saskatchewan Energy Leader Tom Kishchuk, Executive Director of the Global Institute for Energy, Minerals and Society, Joins MAX Power Board as Canada’s First-Ever Natural Hydrogen Drill Program Gets Set To Begin MAX Power Saskatchewan Natural Hydrogen Documentary Videohttps://www.maxpowermining.com/NaturalHydrogen-NewEra/ SASKATOON, Saskatchewan, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; Frankfurt: 89N) (“MAX Power” or the “Company”) is pleased to announce that Mr. Tom ...

CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will host a conference call and webcast on Thursday, November 13, 2025, at 4:30 p.m. ET. Members of the management team will be joined by the below recognized key opinion leaders in cardiovascular medicine to discuss the trea ...

Engagement with FDA on GH001 IND complete response ongoingFull dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025Long-term clinical data on safety and efficacy from Open-Label Extension presented at ECNP in October 2025Cash, cash equivalents and marketable securities of $293.9 million as of September 30, 2025 DUBLIN, Nov. 06, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by devel ...

Accessibility StatementSkip Navigation Chief Digital & Analytics Officer Katya Andresen to lead Excellence & Transformation Initiatives BLOOMFIELD, Conn., Nov. 6, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today announced that Dr. Amy Flaster has been named Chief Medical Officer of The Cigna Group, effective November 1. Dr. Flaster, who joined the company last year as Chief Medical Officer of Cigna Healthcare, will now serve in an expanded enterprise role across both Cigna Healthc ...

A telephone replay of the call will be available approximately two hours after the completion of the call until November 13, 2025. The replay can be accessed via phone by dialing +1 888-660-6264 or +1 646-517-3975 and using playback passcode 76732#. A replay of the audio webcast will also be available in the "Investor Relations" section of the Company's website for twelve months. About Warner Bros. Discovery:Warner Bros. Discovery is a leading global media and entertainment company that creates and distribu ...

Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026 On-track to report data from Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around the end of ...